List of Therapeutic Companies in New York - 219

22nd Century Group, Inc., a biotechnology company, develops plant-based solutions for the life science, consumer product, and pharmaceutical markets. It develops very low nicotine content tobacco and cigarette products under the Moonlight and Moonlight Menthol names; and SPECTRUM research cigarettes for use in independent clinical studies. 22nd Century Group, Inc. has collaboration with Keygene N.V. to develop hemp/cannabis plants for exceptional cannabinoid profiles and other superior agronomic traits for medical, therapeutic, and agricultural uses, as well as other applications. 22nd Century Group, Inc. was founded in 1998 and is headquartered in Williamsville, New York.

A2A Pharmaceuticals designs computationally optimized small molecule therapeutics for the treatment of cancer and antibiotic resistant bacterial infections. Our two oncology programs are focused on inhibiting essential protein-protein interactions in leukemia and in diverse solid tumors. These interactions are critical for cancer progression, but non-essential in normal cells. The antibiotic programs target biosynthetic enzymes in gram-negative bacteria, in pathways not found in humans. The targets selected have no clinically used therapeutics, minimizing susceptibility to resistance; and unlike the numerous follow-on antibiotics currently in development. Our approach integrates interdisciplinary ingenuity with computational tools to design new drug candidates using our proprietary SCULPT platform. Experimentally determined target characteristics guide the selection and placement of fragments to recapitulate key contact points of proteins and/or ligands known to bind. Fragments are incorporated into the target-specific construction of combinatorial in silico libraries, which are designed based on synthetic feasibility. Libraries consisting of thousands to millions of small molecules are iteratively built, and computationally evaluated for potency and optimal ADMET properties. The final selection is made from dozens of iterations, totaling upwards of 100 million compounds.

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Prademagene zamikeracel (pz-cel) is Abeona’s investigational autologous, COL7A1 gene-corrected epidermal sheets currently in development for recessive dystrophic epidermolysis bullosa. The Company’s fully integrated cell and gene therapy cGMP manufacturing facility served as the manufacturing site for pz-cel used in its Phase 3 VIITAL™ trial, and is capable of supporting commercial production of pz-cel upon FDA approval. The Company’s development portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases.

Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or adoptive cell therapies.

Acurx Pharmaceuticals, LLC, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. The company was founded in 2017 and is based in Staten Island, New York.

Aethon takes a novel approach to fighting cancer, creating custom antibody therapeutics that unite immunotherapy and targeted therapy.

AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anti-cancer therapeutics. The Company's platform consists of patented technology from leading universities and researchers and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and University of Maryland at Baltimore . Our diverse pipeline of therapeutics includes therapies for pancreatic cancer and prostate cancer. We are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.

Akelos Inc. is a biopharmaceutical clinical company focused on the translation of innovative science into treatment. The company currently is developing novel non-narcotic drugs for the treatment of neuropathic pain. The goal of Akelos is to address some of today’s most pressing areas of unmet needs. Over 21 million adults suffer from Neuropathic Pain in the US alone†, for which opioid medication is a common treatment. Associated costs exceed $90 billion/year in the US,† and roughly 40 ‐ 70% of people do not receive proper medical treatment and are at risk for either over‐ or under‐treatment.‡ Akelos: Building New Frontiers to Address Neuropathic Pain Akelos is an innovative research-based biotechnology company founded to address the Opioid epidemic through opioid alternatives, with two drug candidates in pre-clinical development. Akelos has proudly entered into a research collaboration to develop and commercialize a novel, non-opioid anti-hyperalgesic drug to treat chronic and neuropathic pain. Akelos holds an exclusive worldwide license with Columbia University and Cornell University and is working in collaboration with Weill Cornell Medicine. Researchers at Weill Cornell University and Columbia University have developed novel compounds for the treatment of neuropathic pain, resulting in intellectual property that is jointly owned by Cornell and Columbia. Akelos has licensed this intellectual property and is developing a treatment for neuropathic pain using the novel compounds.

Alpha-1 Biologics is a biotherapeutics company developing innovative treatments for cancers and immune deficiencies. The company is dedicated to their mission to develop patented therapeutics related to the generation of immune cells from stem cells within the body to treat immunodeficiency with disease applications including immune cell replenishment in cancer therapy, HIV/AIDS, patients with inherited deficiency of α1PI, and in the most prevalent cause of immune deficiency, malnutrition. Alpha-1 Biologics is currently testing their orally-available, small molecules in studies to determine their ability to increase the number of tumor infiltrating CD4+ T cells and coordinate with immune checkpoint inhibitors to eliminate tumors. The discoveries at the core of Alpha-1 Biologics therapeutic approach resulted from basic research conducted by Dr. Bristow and supported for many years by the non-profit research organization, Institute for Human Genetics and Biochemistry (IHGB) funded by the Harry Winston Research Foundation.

Alphageneron Pharmaceuticals, Inc., is a privately-held clinical stage biotechnology company, developing Antibody Drug Conjugates (ADCs) and natural killer (NK) cell therapies, supported by Companion Diagnostics. Our team are industry veterans with experience in both large pharma and biotechnology startups committed to transforming the lives of cancer patients.

ALR Technologies is a medical device company providing remote monitoring and care facilitation for patients with diabetes. ALRT has developed the FDA-cleared Health-e-Connect System which uploads the data from blood glucose meters onto a secure website where clinicians and Diabetes Care Facilitators can better monitor and coordinate the care of diabetes patients. ALRT's system goal is to assist patients to adhere to their care plan, improving the quality of diabetes care and making such care more cost effective to providers

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company focused on developing treatments for debilitating neurodegenerative and neurodevelopmental diseases. The Company’s lead product candidate, ANAVEX®2-73 is undergoing four mid- to late-stage clinical trial programs for CNS diseases where no good treatment options exist, or current treatments are inadequate. These include Alzheimer’s disease (Phase 2b/3) and Parkinson’s disease dementia (Phase 2), which are neurodegenerative diseases that are on the rise due to aging populations in developed nations. Additionally, Anavex has two ongoing Phase 2 trials for Rett syndrome, a neurodevelopmental disease that mostly affects young female girls. Anavex has received Orphan Drug Designation from both the FDA and EMA for Rett syndrome. ANAVEX®2-73 has potential to treat other CNS disorders, given its ability to restore upstream cellular homeostasis. Anavex has received funding from Rett Syndrome Foundation, as well as Michael J Fox Foundation supporting Anavex’s studies. Anavex has identified a novel biomarker signature (genetic variants) that have potential to determine which patients will benefit the most from ANAVEX®2-73, which targets the Sigma-1 receptor (SIGMAR1), a natural cell signaling pathway that is activated to restore cellular homeostasis.

Ancilia is harnessing the natural power of CRISPR to develop a new class of bacterial therapies and products for a range of applications.

AnHeart Therapeutics is a clinical-stage global biopharmaceutical group company developing a broad pipeline of novel precision oncology therapeutics with high unmet medical needs. Its lead asset, taletrectinib, is a best-in-class next-generation ROS1 inhibitor currently in Phase 2 trials for the first-line TKI-naïve and second-line TKI-pre-treated patients with ROS1 fusion positive non-small cell lung cancer (NSCLC). The Company's pipeline also includes AB-218, a mIDH1 inhibitor in Phase 2 trials with good brain penetration for multiple solid tumors with mIDH1 mutations and AB-329, an AXL inhibitor in Phase 1 studies to be used in combination with checkpoint inhibitor or chemotherapies in NSCLC or other solid tumors.

Apertura is a biotechnology company opening opportunities in gene therapy for treating debilitating diseases with limited options. We are pioneering next-generation AAV gene therapies by simultaneously engineering capsids, regulatory elements, and payloads to overcome current limitations in genetic medicine. Founded on technologies from the Broad Institute and Harvard University, and with support from Deerfield Management Company, we are located at the Cure in New York City.

Develops DNA Security Tags, Molecular diagnostics, and vaccines.COVID-19: Applied DNA and Takis Biotech completed the design of a diagnostic kit for SARS-COV-2 (the virus that causes the disease COVID-19) being developed for production via the company’s proprietary PCR-based DNA (LineaRx™) manufacturing process. They also work with Takis on vaccines. EUA (05/2020)

Applied Therapeutics is a clinical-stage biopharmaceutical company that uses our novel drug-development approach to create transformative, life-changing treatments for the patients who desperately need them.

AptaMatrix is a privately held, start-up biotechnology company headquartered in Syracuse, New York. The company's focus is to accelerate the rate of aptamer discovery using its patent pending High Throughput Screening of Aptamers (HTSA) approach in addition to developing its novel AlloSwitch™ sensor technology capable of a) creating rapid diagnostic tools for detection of chemical and biological targets, and b) leveraging this diagnostic platform for drug discovery applications. AlloSwitches™, have demonstrated the ability to transduce molecular recognition of biological targets into a real-time (seconds) optical signal for identifying environmental and terrorist released contaminants in liquid systems. HTSA and AlloSwitch solutions are built on patented biotechnology based on years of leading-edge biological research and industry partnerships at Syracuse University. The HTSA approach leverages the high throughput capabilities of deep-sequencing technology. All sequencing activity is managed by our Genomics Division and conducted on our Illumina GAIIx platforms. Data analysis is supported by our in-house bioinformatics team. In addition to supporting internal research and development, our genomics division actively supports both academic and commercial deep-sequencing projects.

Aquavit Pharmaceuticals, Inc. is a multi-specialty health care company focused on discovering, developing and commercializing innovative pharmaceuticals, medical devices and health technologies. We focus on personalized medicine to improve patient health and to maximize the efficiency of the medical community. At Aquavit Pharmaceuticals, Inc., we combine this strategic focus with a modern, diverse approach that enables us to pursue new specialty areas with significant unmet needs. Science personalized. Healthcare modernized.

ARMGO is a privately owned, venture-backed, biotech company that is developing small molecule drugs that repair leaky Ryanodine Receptor (RyR) calcium channels associated with human diseases. Our primary focus is on two orphan diseases: the life-threatening cardiac disease Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT), and the severe muscle disease RYR1-Related Myopathy (RYR1-RM). These two conditions occur due to genetic mutations in the RYR gene: RYR1 in RYR1-RM, and RYR2 in most CPVT cases. ARMGO’s molecules, termed Rycals® are designed to repair leaky RyR channels. Since the cause of the symptoms is abnormal calcium leak due to these mutations, Rycals hold the promise of disease-modifying therapy for these two orphan genetic diseases.

Developing Novel Therapies for Multiple Sclerosis

We are a full service provider that specializes in the treatment of autism and other developmental disabilities. Our broad thinking approach addresses the whole child by collaborating with doctors, therapists, schools and specialists. Our goal is to work together to achieve the best possible outcome… PROGRESS! Autism Learning Partners is proud to play a key leadership role in the ASD community. Our company name reflects our commitment to children with Autism and their families. AUTISM: We have the word Autism in our name to clearly identify the community we primarily serve and allow that community to easily identify and find us when seeking a care provider for their ASD needs. We do serve children with developmental needs other than Autism, but the vast majority of clients we serve are on the spectrum and, as such, our central mission is focused on serving the ASD community. LEARNING: The word "Learning" refers to the science of Applied Behavioral Analysis being the science of learning across all areas of development. By having "Learning" in our name, we clearly acknowledge and convey that we are focused on the science of learning and its role in improving communication, social relationships, schooling and, ultimately, a positive work/life experience. PARTNERS: Finally, the word "Partners" emphasizes how we think about our approach as a care delivery organization. Today, the community calls for a far more integrated approach in terms of communication, medical records and "partnerships" with other providers to support a more multi-disciplinary and comprehensive approach to care for clients and patients. Whether those professionals are your child's pediatrician or psychologist, school teacher or speech therapist, our willingness to reach out and partner with other healthcare and educational professionals in our clients' lives creates a meaningful difference in his or her progress and development.

Auxilius Pharma is an emerging specialized pharmaceutical company with a focus on further developing and optimizing medications well established in some markets but not in the others, for the benefit of patients and to address major unmet needs in an increasingly cost conscious health care market environment. We are a versatile team with multifunctional healthcare experience in both the US and EU. We feature diverse backgrounds and strong core competencies in pharmaceutical marketing, drug development, pharmacology, health care management, corporate finance, and asset management.

AXIM Biotechnologies is an innovative biotechnology company focusing on research, development and production of pharmaceutical, nutraceutical, and cosmetic products as well as alternative energy sources. We prioritize the well-being of our customers while embracing a solid fiscal strategy. We believe in setting the green standard for cannabinoid bioscience through the discovery and commercialization of new materials and technologies for healthy living while respecting the environment. Public Relations Contact Andrew Hard Chief Executive Officer CMW Media andrew.hard@cmwmedia.com P. +1888 829-0070 www.cmwmedia.com Investor Relations Contact Shiwei Yin, Grayling Shiwei.Yin@grayling.com P. +1646 824-2857 Lucia Domville, Grayling lucia.domville@grayling.com P. +1646 284-9416

Our Mission: For the many people facing unsatisfactory treatments for CNS disorders, Axsome accelerates the invention and adoption of life-changing medicines

Azure Biotech is a biotechnology company that specializes in developing a novel formulation of lasofoxifene targeting an underserved market in women's health.

Beyond Air Inc. is a commercial stage medical device and biopharmaceutical company focused on harnessing nitric oxide therapy. The company is built on a legacy of innovation and is revolutionizing nitric oxide therapy. Beyond Air Inc. has experience and leadership that go beyond, with a team of industry professionals dedicated to advancing medical treatment. For more information, visit https://www.beyondair.net/

BeyondSpring Pharmaceuticals is a global biopharmaceutical company focused on developing innovative cancer therapies to improve clinical outcomes. The Company is developing treatments in two of the world’s largest markets, China and the United States. BeyondSpring’s first-in-class lead asset plinabulin, a selective immunomodulating microtubule-binding agent, is being developed as a “pipeline in a drug” with potential to be an anti-cancer agent and to prevent chemotherapy-induced neutropenia (CIN). In the DUBLIN-3 Phase 3 study, the plinabulin and docetaxel combination met the primary endpoint of extending overall survival, compared to docetaxel alone in 2nd/3rd line non-small cell lung cancer (EGFR wild type). In addition, the plinabulin and G-CSF combination for the prevention of CIN has demonstrated positive Phase 3 data, for which it received Breakthrough status in the U.S. and China. Plinabulin is also currently being studied as part of other immuno-oncology (IO) combination regimens that include radiation and/or checkpoint inhibitors for the treatment of a number of cancers. Lastly, BeyondSpring also has three preclinical IO assets and majority ownership in its subsidiary, SEED Therapeutics, which is leveraging a proprietary targeted protein degradation drug discovery platform.

BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders: • Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of protruding and bulging lumbar discs in patients suffering from chronic lumbar disc disease. The BRTX-100 production process involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have received clearance from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain due to degenerative disc disease related to protruding/bulging discs. • Metabolic Program (ThermoStem®): We are developing a cell-based therapy to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (“BAT”). BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes.

Biotia is a health tech company launched from Jacobs Technion-Cornell Institute at Cornell Tech in association with Weill Cornell Medicine, located in New York, NY, that leverages DNA sequencing-based technology and proprietary AI-powered software to rapidly and accurately identify microorganisms and antimicrobial resistance. Biotia is developing a next-generation sequencing-based test for COVID-19 that characterizes genetic variance across the whole viral genome.

Bond Biosciences, Inc. is a privately held, clinical stage biopharmaceutical company focused on the discovery and development of first-in-class non-absorbed oral therapeutics that bind excess ions locally in the gastrointestinal (GI) tract to treat or prevent human disease.

BrainStorm Cell Therapeutics Inc. (NASDAQ) develops autologous stem cell therapies for neurodegenerative disorders such as ALS, MS, and Parkinson’s disease. These diseases have limited treatment options and represent unmet medical needs. NurOwn® is BrainStorm’s proprietary process for differentiating autologous mesenchymal stem cells (MSC) into neurotrophic factor (NTF)-secreting cells, transplanted at or near the affected tissue site. Our technology converts MSCs into a living drug delivery system for NTFs. We have proof-of-concept in various animal models of neurodegenerative diseases, including Parkinson's, Huntington's, ALS, MS, and peripheral nerve injury. We have completed two single-arm clinical trials in ALS patients in Israel, demonstrating good safety and tolerability profiles and strong efficacy signals. We also finalized a Phase 3 randomized, double-blind, placebo-controlled clinical trial at multiple US sites, supported by a $16 million USD grant from the California Institute for Regenerative Medicine (CIRM) and another grant from the ALS Association. Currently, we are planning a Phase 3b clinical trial of NurOwn® in ALS under a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA). For more information, visit www.brainstorm-cell.com

BBI, headquartered in New York, is a privately held company founded in 2010 that specializes in acquiring and developing pharmaceutical and biotechnology products intended for the treatment and/or prevention of serious unmet medical needs. The COMPANY’s focus is to develop its products as quickly and as efficiently as possible, saving time and resources. We have partnered with leading academic institutions as well as a global network of drug development resources, eliminating the need and cost to build a "brick and mortar" biotech company. This innovative approach gives BBI big pharma capabilities without a big pharma infrastructure.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company’s products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Calder Biosciences, Inc. is a nano-scale molecular engineering company that is applying its platform technology to develop novel respiratory syncytial virus (RSV) and universal Influenza vaccines that both represent multi-billion dollar market opportunities with mitigated clinical risk.

Calliditas is a clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs.

Cambrian Bio is building the medicines that will modernize healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health.

Canget BioTekpharma is a biotech and biopharma company used to develop novel, cancer-targeting anticancer agents.

CastleVax uses Newcastle Disease Virus (NDV) as a platform for rapidly developing safe and highly immunogenic viral vectors for use as vaccines, that are easy to deliver and store, and can be administered via injection or intranasally.

CD BioGlyco provides various carbohydrates, glycoconjugates, enzymes and related products, as well as many glycobiology related research services.

Celyad Oncology is a cutting-edge biotechnology company dedicated to pioneering the discovery and advancement of revolutionary technologies for chimeric antigen receptor (CAR) T-cells. Its primary objective is to unlock the potential of its proprietary technology platforms and intellectual property, enabling to be at the forefront of developing next-generation CAR T-cell therapies. By fully leveraging its innovative technology platforms, Celyad Oncology aims to maximize the transformative impact of its candidate CAR T-cell therapies and redefine the future of CAR T-cell treatments. Celyad Oncology is based in Mont-Saint-Guibert, Belgium. For more information, please visit www.celyad.com.

Our flagship methylarginine-specific antibody, anti-mRG, is specifically designed to recognize the greatest number of methylproteins currently known. The immunizing antigen is based on a site of methylation found in a minimally required peptide sequence of consensus for arginine methylation.This tool provides a fundamental advantage for research that is exploring the importance of protein methylation in biological systems.

Channavix Therapeutics, LLC is developing a portfolio of novel, non-addictive, non-opioid analgesics that provide multi-week pain relief with local administration. The business and scientific team that has been assembled for Channavix has a long history of working in the field of pain management and drug development. Channavix is dedicated to the discovery of novel therapeutics for neurological disorders such as pain, with a mission to improve patient outcomes and address the global opioid problem.

Chemeleon has created a platform technology for the rapid, instrument-free, detection of chemical compounds in the field, obviating the need for slow, complex, and expensive lab analysis. Our sensor materials combine highly selective molecular receptors with colorimetric nanomaterial reporters to provide an autonomous and inert means of optically detecting hazardous chemicals in virtually any environment, from clinical to third-world settings.

Chimerna Therapeutics is a biotech company focused on RNA therapeutics. Their platform for generating circular RNA overcomes the major limitations of RNA therapeutics, such as stability and abundance.

Perfecting the Sense of Sight. Clerio Vision is developing a revolutionary product platform for the global ophthalmic market, based on technology licensed from the University of Rochester. The company is in the process of developing and commercializing a portfolio of next generation products in contact lenses, myopia control and cataract surgery. The team is composed of serial entrepreneurs with multiple exits as well as ophthalmic industry veterans who pioneered a number of new ophthalmic technology categories. The products are currently in clinical development.

Click Therapeutics, Inc., develops, validates, and commercializes software as prescription medical treatments for people with unmet medical needs. As a leading innovator of Digital Therapeutics™, we deliver accessible, clinically proven, FDA-regulated prescription treatments to the smartphone in your hand. Our treatments are defined by our commitment to applying technical and scientific rigor and patient-centric design to the development process. This results in uniquely engaging experiences that achieve compelling clinical outcomes for patients seeking new treatment options. We are continuously expanding and refining our shared platform technologies with novel cognitive, behavioral and neuromodulatory mechanisms of action and advanced data-driven tools such as artificial intelligence and machine learning. Digital therapeutics under development on our platform address diverse areas of therapeutic need, including indications in psychiatry, neurology, oncology, cardiology and immunology. Consistently named a best place to work, we foster an inclusive, diverse workforce of innovators, clinicians, scientists, researchers, designers, technologists, engineers and more, united in our mission to provide patients everywhere access to safe and effective prescription digital therapeutics. NOTE: Fake job advertisements and offers are increasingly appearing on the internet. If you have encountered a job posting or have been approached with a job offer that you suspect may be fraudulent, we strongly recommend you do not respond and report it to the Federal Trade Commission and to recruitment@clicktherapeutics.com. Other than your email address or telephone number, which you may provide via a job application portal, Click Therapeutics will never ask you to provide personally identifiable information about yourself (such as a Social Security Number or Driver’s License Number) via a messaging application.

CLS Therapeutics is a biopharmaceutical firm that provides transformative gene therapy solutions for cancer patients.

CMTx Biotech is commercializing a pipeline of proprietary, non-antibiotic, chemically-modified tetracycline (CMT) compositions and formulations for the host-modulatory treatment of diseases with high unmet needs. The company’s lead drug candidate is a clinical-stage, orally-administered small molecule (incyclinide / CMT-3 / COL-3) for the treatment of hospitalized sepsis patients at risk of septic shock, multiple organ dysfunction syndrome (MODS) and acute respiratory distress syndrome (ARDS), including from SARS-CoV-2 infection (COVID-19) and other infectious diseases. Our clinical-stage drug candidate has already demonstrated impressive efficacy in a number of animal models of sepsis/ARDS/MODS across multiple species (rats, mice, pigs, sheep). It has also been evaluated in over 450 patients across eleven Phase I/II clinical studies, which showed that the drug is well-tolerated. CMTx Biotech also has a pipeline of pre-clinical stage analogues for the treatment of diseases with high unmet need.

Codagenix Inc. is a clinical stage biotechnology company with vaccine products against influenza, respiratory syncytial virus, dengue virus, and others currently under development. Codagenix uses a computer-based algorithm, called SAVE (Synthetic Attenuated Virus Engineering) to design viral genomes that are identical to the wild type strain at the amino acid level, but make less protein in human cells. The highly attenuated viruses make excellent vaccines or oncolytics against solid tumors. Codagenix represents the next wave in vaccine technology, untethered from traditional, time-consuming and unpredictable approaches to attenuating viruses.

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in phase 2 clinical trial for the treatment of mild-to-moderate Alzheimer’s disease, as well as has completed phase 1 clinical trial to treat early-stage Alzheimer’s disease; and in preclinical trial to treat dementia with Lewy bodies (DLB) and dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson’s disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.

ConSynance is a clinical-stage virtual biopharmaceutical company focusing on rare diseases in the central nervous system. Our lead asset is CSTI-500, a small molecule first-in-class triple monoamine reuptake inhibitor (TRI) with the potential to benefit patients with Prader-Willi syndrome (PWS) and other related disorders. CSTI-500 was generally safe and well-tolerated in Phase I clinical trials in healthy humans and demonstrated CNS target engagement via PET that predicts efficacy in patients. ConSynance is currently recruiting for a Phase I study in PWS patients (clinicaltrials.gov: NCT05504395) to study the pharmacokinetics and safety in this patient population. We also have a preclinical candidate, CSTI-200, a small molecule, first-in-class GlyT-1 Inhibitor for the treatment of L-Dopa-induced dyskinesia (LID) in Parkinson’s disease (PD). Based on recent preclinical evidence, GlyT1 inhibition may have a niche in PD not only for the treatment of dyskinesia, but motor fluctuations and PD psychosis. CSTI-200 has a competitive mechanism of binding that provides a “self-regulating” property for potentially better tolerability compared with non-competitive GlyT-1 inhibitors. In 2021, we reached an asset purchase agreement with Harmony Biosciences for our second drug, (formerly CSTI-100, now renamed HBS-102.) This potential first-in-class MCHR1 antagonist has the potential to treat a variety of neurological disorders. ConSynance currently holds the license of this drug for the Greater China region and Harmony has global commercialization rights outside of Greater China.

Headquartered in Brooklyn, New York, Cresilon, Inc. is a privately-held medical device company focused on hemostatic technologies that improve wound care and advance the standard of medical treatments. For more information, visit Cresilon.com. We are always looking for dynamic people to join our team as we dive into a range of challenges at the forefront of science and technology—to learn more about our openings please visit https://cresilon.workable.com/.

CryptoMedix is a biotech company in the field of Oncology, developing highly innovative treatments for cancer.

Curemark is a clinical-stage biopharmaceutical company dedicated to advancing innovative therapies for neurological and developmental disorders. Our diverse pipeline spans multiple critical areas of unmet need, including Autism Spectrum Disorder (ASD), Amyotrophic Lateral Sclerosis (ALS), Addiction, Attention-Deficit/Hyperactivity Disorder (ADHD), Schizophrenia, and Parkinson’s Disease. At the heart of our mission is a commitment to addressing the root causes of these conditions, not just managing symptoms. Our lead investigational therapy targets key enzyme deficiencies associated with autism, offering a novel approach to treatment for a condition that affects millions worldwide. Our pipeline reflects a science-driven, patient-first approach with a focus on discovering and developing transformative therapies for complex neurological conditions. By exploring the role of enzymes and their impact on brain function, Curemark aims to deliver targeted, effective treatments that improve patient outcomes. With a commitment to scientific excellence, strategic collaboration, and a deep focus on patient well-being, Curemark is reshaping the future of neurological care. Our goal is to offer life-changing solutions for individuals living with autism, ALS, addiction, ADHD, schizophrenia, Parkinson’s disease, and other challenging conditions. Stay connected with us as we continue to push the boundaries of discovery and bring new hope to patients, families, and caregivers. For more information, visit Curemark.com.

Cypris Therapeutics is a chemistry-focused pharmaceutical start-up that uses proprietary synthetic chemistry and drug development skills to produce effective therapeutics. The company has launched as the newest Ichor Life Sciences portfolio company and has secured over $500k in pre-seed funding. As the company moves forward, it continues to seek additional funding and partnerships to support its ambitious goals.

Delcath Systems, Inc. (NASDAQ- DCTH) is a specialty pharmaceutical and medical device company focused on the treatment of primary and metastatic liver cancers. Our proprietary product---Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS)---is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure. Delcath is in late-stage clinical development in the United States with initial commercial activities in Europe, where the Melphalan/HDS is marketed as a CE Marked device under the trade name Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT). Our commercial strategy for CHEMOSAT is to steadily grow clinical adoption in major European markets and utilize physician experience to support appeals for reimbursement. Since launch over 250 CHEMOSAT treatments have been performed at over 20 leading European cancer centers. In 2016, we launched our FOCUS Pivotal Study in Hepatic Dominant Ocular Melanoma, and are investigating orphan indications in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. We believe Melphalan/HDS is uniquely positioned to treat the entire liver as a stand-alone or complementary therapy.

DepYmed is currently developing potent inhibitors of the enzyme PTP1B as therapeutics for cancer and rare diseases. In addition, DepYmed has developed a portfolio of novel small molecules with copper chelating properties that can be applied as potential therapeutic agents for multiple diseases including Wilson Disease and cancer. ​

Private biotech company leveraging immuno-metabolism to create a potential new treatment paradigm with broad application for many cancer types.

Elucida Oncology is a biotechnology company that pioneers targeted cancer therapy with ultra-small nanoparticle C’Dot drug conjugates designed to penetrate deep into tumors.

Emendo Biotherapeutics develops next generation gene editing tools for genetic disorders, addressing the current technological gaps for realizing the promise of gene therapy. We leverage our expertise in protein engineering to bring innovative and disruptive protein tools to resolve the bottleneck of the field.

Empyrean is harnessing the power of genetic engineering to transform how we treat severe neuropsychiatric and neurologic diseases.

ENB Therapeutics is developing therapies to break drug resistance that occurs in over 50% of cancer patients. Our lead product, ENB-001, is a first-in-class, selective small molecule endothelin B receptor (ETBR) inhibitor shown in multiple preclinical studies to significantly reduce tumor growth and prolong survival in cancer animal models. ENB-001 is the key to unlock the full therapeutic potential of immunotherapy by restoring the ability of T-cells to infiltrate tumors, inhibiting metastasis and prolonging patient survival. Granted Orphan Drug Designation by FDA in 2016, ENB-001 has solid market exclusivity and strong IP. A low cost, time efficient development program provides near-term POC within 18 months from financing. A companion diagnostic will detect ETBR pathway over-expressers creating additional opportunities for indication expansion into multiple tumor types and broader participation in the multi-billion-dollar immunotherapy market.

Envisagenics was founded in 2014 as a spinout of Cold Spring Harbor Laboratory. Our mission is to reduce the complexity of biomedical data to accelerate the development of innovative therapeutic solutions through RNA splicing analytics and artificial intelligence. We focus on the discovery of RNA therapeutics. Over 30 million people in the US suffer from genetic diseases or cancer that could be caused by mutations affecting RNA splicing. 370 human diseases are known to be caused by splicing errors, and more remain to be discovered. Our breakthrough technology, SpliceCore, is a cloud-based platform that is experimentally validated to predict drug targets and biomarkers through splicing discovery from RNA-seq data, using Artificial Intelligence. We are using our software to identify splicing errors causative of diseases, identify the right drug-targets and develop RNA therapeutics through partnerships and collaborations with Biopharma. Our in-silico RNA therapeutics discovery platform replaces expensive drug-target selection and lead design with efficient computer simulations, decreasing time, cost, and failure risk of drug development programs.

EyeBio is a privately held ophthalmology biotechnology company dedicated to developing and delivering a new generation of therapies to protect, restore, and improve vision in patients with sight-threatening eye diseases.

Eyenovia, Inc. (NASDAQ: EYEN) is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for microdosing. Eyenovia’s pipeline is currently focused on the late-stage development of microdosed medications for myopia progression, presbyopia, mydriasis and other eye diseases.

Formation Bio is a tech-driven pharmaceutical company differentiated by radically more efficient drug development. Formation Bio has built a technology platform that optimizes critical aspects of clinical drug development, enabling more efficient trial design, faster trial completion, and higher quality trial data. The company acquires clinical-stage drugs from pharmaceutical and biotech companies with the goal to develop them faster in order to accelerate access to new treatments for patients, and to unlock greater value per program.

For-Robin Therapeutics, (F-R), is an antibody immunotherapy company, founded in 2012 by Dr. Kate Rittenhouse-Olson. The company name is in honor of Robin Quataert, the Founder’s sister, who died at age 31 of estrogen and progesterone receptor negative breast cancer. For-Robin’s primary mission is treating breast cancer patients. Our proprietary technology (the monoclonal antibody JAA-F11 and humanized variants of it) targets all breast cancer cell subtypes including triple negative breast cancer which currently has no targeted therapy. In addition, this technology should be applicable to colon, prostate, and bladder carcinoma patient populations. For-Robin plans to bring its core humanized JAA-F11 technology as an adjunct therapy to patient populations as quickly, safely and efficaciously as possible.

FREZENT is a preclinical stage oncology therapeutics company based in New York. The company is developing bispecific antibodies and antibody-drug conjugates for targeting dormant cancer cells that may cause cancer recurrence. Dormant cancer cells are tiny residual parts of a tumor, that was not completely eliminated by the treatment. They can remain in the body undetectable for a period of time but eventually these cells can transform back into a fast growing tumor. FREZENT is developing a novel cancer treatment that will block the reactivation of dormant cancer cells. To achieve this goal, we are developing novel cancer therapeutic that can neutralize metabolic factors supplied tumor microenvironment to support the dormant cancer cells. Being in a dormant state, cancer cells depend on these external supplies, and thus blocking this supply will starve cancer cells and induce cell death. Join us in our mission to ensure the future where long-lasting remission is the reality for ALL cancer patients.

Gameto is a biotechnology company whose mission is to redefine female reproductive health by developing therapies that improve lives. Women’s health is a vastly underserved therapeutic area. Most conditions have few treatment options, and those available often cause frequent complications and offer limited clinical benefit. We aim to change that. Gameto is committed to using cutting-edge scientific advances to deliver better solutions to patients. Using cellular engineering, we have developed a platform to produce female reproductive cell lines. We use proprietary combinations of transcription factors to reprogram hiPSCs into engineered ovarian and endometrium cell lines that mimic the functions of endogenous cells, producing and responding to all hormones. Our team of cellular engineers is using this platform to advance a portfolio of cellular therapeutics for female reproductive diseases. Our first program, Fertilo, is a therapeutic for IVF and egg freezing, aiming to make the process shorter, safer and more effective. Additional applications of our platform include, an organoid of the female reproductive system, Deovo, and a cell-based therapeutic to ameliorate the health consequences of primary ovarian insufficiency and menopause, Ameno.

Gilgamesh is a clinical-stage biotech whose vision is to reshape how mental illnesses are treated by shifting away from symptom management to a focus on rapid-acting and durable therapies targeting the fundamental drivers of disease. We do this by designing best-in-class new chemical entities (NCEs) acting through proven mechanisms, which are optimized for safety, efficacy, and patient access

Neurodevelopmental disorders represent significant areas of unmet need in healthcare. People affected by these disorders, predominantly children and young adults, can face a range of severe and devastating symptoms. In many cases, there are only limited or no treatments available. GRIN Therapeutics is dedicated to the research and development of precision therapeutics for pediatric neurodevelopmental disorders with the goal of bringing hope to patients and caregivers.

Helaina isworking to grow mammary cells toproduce cultured human milkforhuman babies.

Helex is taking the promise of non-viral targeted delivery and genome editing to the kidney, developing first-in-class genetic medicines for renal indications. Helex combines its proprietary kidney tropic lipid nanoparticle delivery system with the Epic-Cure(TM) 3D genome-based drug designer platform to create a robust renal franchise of precise and scalable therapeutics. Our lead asset is a mutation-agnostic, potential one-and-done therapy for Autosomal Dominant Polycystic Kidney Disease that impacts over 4 million people worldwide.

Helocyte, Inc. (“Helocyte”), a company founded by Fortress Biotech, Inc., is focused on the development and commercialization of novel immunotherapies for the prevention and treatment of cancer and infectious disease (in particular, cytomegalovirus or “CMV”)

Hemogenyx Pharmaceuticals PLC is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located at its state-of-the-art research facility in New York City. For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. Hemogenyx Pharmaceuticals plc’s technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation. Hemogenyx Pharmaceuticals PLC is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. The Company is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.

HiberCell is a clinical stage oncology company, dedicated to the advancement of first-in-class agents with the novel MOA of modulation of adaptive stress pathways and anti-tumor immunity. We believe that therapeutic modulation of these mechanisms allows us to address tumor metastasis, treatment resistance, and cancer relapse; all significant drivers of cancer-related deaths. Our product candidates HC-5404 and HC-7366, both completing Phase 1a clinical trials, target the stress response kinases PERK and GCN2, respectively, while our product candidate odetiglucan, currently in Phase 2 clinical development, modulates the anti-tumor innate immune response.

At HOOKIPA, we envision a world in which cancers and infectious diseases can be chronically managed or eradicated. HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company advancing the field of immunotherapy through the development of new immunotherapies based on our proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. Our pipeline includes wholly owned investigational arenaviral immunotherapies targeting HPV16+ cancers, prostate cancer, KRAS-mutated cancers (including colorectal, pancreatic and lung), and other undisclosed programs. In addition, HOOKIPA aims to develop functional cures for HBV and HIV in collaboration with Gilead. As a company, we fight for innovation; we challenge ourselves to act authentically and transparently; we thrive on our differences; and we go for it, never giving up in our efforts to eliminate the suffering of people with cancer and infectious disease. To learn more please visit www.hookipapharma.com.

At Hoth Therapeutics, Inc. (NASDAQ: HOTH), we strive to develop innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating promising drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate medications that hold immense potential to create breakthroughs and diversify treatment options.

Humane Genomics is developing a platform to engineer cancer killing viruses with unprecedented specificity and efficiency. Our first indication is liver cancer. We are based in New York City and backed by amazing investors. (YC S21)

Translating scientific discoveries into affordable, globally accessible public health solutions. IAVI is a non-profit that develops vaccines and antibodies for HIV, tuberculosis, and emerging infectious diseases.

iCell Gene Therapeutics is developing Chimeric Antigen Receptor (CAR) engineered cells with improved functional properties and expanded applicability. We are a clinical stage company focused to demonstrate clinical proof of concept for unique, patent protected, targets and strategies. Our pipeline includes multiple additional first in man CAR strategies to target hematological cancers, non-hematological cancers and autoimmune disorders.

Ichnos Sciences is a global clinical-stage biotechnology company developing innovative multispecific antibodies for oncology and disease-centric therapies.

ICPD began by integrating pre-clinical and clinical data through modeling and simulation to improve how antibiotic resistance is defined in the clinical microbiology laboratory. ICPD then ignited the use of PK-PD-based dose regimen selection that now ensures optimal patient drug exposures and thus, an increased likelihood of successful response during the antibiotic development process. ICPD educates drug regulators and pharmaceutical and biotechnology companies on PK-PD-based strategies to make certain safe and effective antibiotics are available to thwart the growing threat of antibiotic-resistance. ICPD Technologies has used the foundation laid by ICPD and others to develop a mobile device application that provides PK-PD education to clinicians. Through the revolutionary PK-PD Compass, ICPD Technologies will carry out a mission to educate clinicians and improve antibiotic stewardship efforts worldwide.

ILGEN is a biopharmaceutical company propelling medicine on novel proprietary biotechnology. They are the first-in-class, naturally occurring LAG3 checkpoint inhibitor.

Comprehensively mapping the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development and improve patient outcomes.

Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn’s disease, and psoriasis.

Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com. For U.S. residents only.

Immunyx Pharma is focused on changing the landscape of immune modulation by targeting neutrophil toxicity in numerous chronic diseases. The company was built by world leaders in neutrophil biology and nanoparticle delivery to use a targeted neutrophil nanoparticle platform (TENNs) to solve the significant issues in neutrophil therapy. While big pharma has invested heavily in neutrophil targeted drugs, they have failed to bring solutions to the clinic due to the danger of causing neutropenia and the difficulty of modulating such a large & dynamic population of cells. Our TENN platform is intended to manipulate neutrophil toxic behavior without destroying their disease fighting function, while bringing a concentrated payload of drug to all neutrophils throughout the body with a long bioavailability. We are currently focusing on applying our platform to modulate neutrophil activity in cancer and inflammatory disease.

IN8bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancer. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems, and can intrinsically differentiate between healthy and diseased tissue. IN8bio develops ex vivo-expanded and activated gamma-delta T cells based upon its deep expertise in gamma-delta T cell biology, proprietary genetic engineering, and cell-type specific manufacturing capabilities, which we refer to collectively as our DeltEx platform. IN8bio’s platform employs allogeneic, autologous, and genetically modified approaches to develop novel cell therapies, which are designed to effectively identify and eradicate tumor cells. IN8bio is currently the most clinically advanced gamma-delta T cell company and the first company to bring genetically modified gamma-delta T cells into the clinic. For more information about the Company and its programs, visit www.IN8bio.com.

The Indaptus Goal is Simple: to Cure Disease With the ability to harness both the body’s innate and adaptive immune responses, we believe we are uniquely positioned to revolutionize the treatment of cancer and certain infectious diseases. Building on the observation that tumor regression can occur in the setting of bacterial infection, we have developed a proprietary platform that exploits bacteria’s natural ability to activate both innate and adaptive cellular immune pathways. Leveraging our novel insights into the levels and ratios of activating signals needed to safely elicit a broad immune response, we are creating and advancing a pipeline of proprietary, attenuated and killed non-pathogenic gram-negative bacterial candidates designed to be widely accessible, with broad anti-tumor and anti-viral activity.

Inductive Bio is a biotechnology company based in San Francisco, California, founded in 2022. The company specializes in using advanced machine learning and data analytics to enhance the compound optimization process in small molecule drug discovery. With a seed funding of $4.3 million, Inductive Bio aims to address challenges in Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) during drug development. The company's core offering is a proprietary dataset combined with sophisticated machine learning models. This platform enables scientists to efficiently optimize initial compounds into viable leads and development candidates, providing real-time predictions and insights throughout the drug design process. Inductive Bio collaborates with pharmaceutical companies, biotech firms, and research institutions, including a partnership with Nested Therapeutics focused on precision medicine for challenging cancers.

Innervace is a regenerative therapy company developing technology that acts as pre-formed, anatomically-inspired, implantable tissue pathways to directly replace lost connections due to brain degeneration or injury. Our lead program mimics the lost migrostriatal pathway in patients with Parkinson's disease (PD).

INNOVIMMUNE is a specialty Drug Discovery & Exploratory Development biotechnology company leading the development of novel first-in-class and best-in-class proprietary oral small molecule NME immunomodulatory drugs for the treatment of Autoimmune, Inflammatory and Oncologic Diseases. Follow us on Twitter: @Innovimmune

Inspirna is developing first-in-class drugs that target key pathways in cancer progression. Using a discovery platform developed by Inspirna's founding scientists at Rockefeller University, we have discovered several novel cancer targets that drive tumor growth and cancer progression. These targets regulate key components of the tumor micro-environment including immune cells and cancer metabolism pathways. Our discovery platform - which can be applied to virtually any tumor type - has yielded novel therapeutic targets for several high-unmet need cancer types to date. We aim to develop effective therapies against these targets that will provide durable and meaningful responses for cancer patients that lack effective therapies. Our lead therapy RGX-104 is a small molecule immunotherapy that blocks the ability of tumors to evade the immune system. RGX-104 has obtained FDA Orphan Drug Designation in several solid tumor types of high-unmet need and entered clinical trials in Q4 2016.

Intra-Cellular Therapies, Inc. is a biopharmaceutical company founded on Nobel prize-winning research that allows it to understand how therapies affect the inner-workings of cells in the body. The Company leverages this intracellular approach to deliver innovative treatments for people living with complex psychiatric and neurologic diseases. WORK WITH US Patient needs are at the core of our efforts at Intra-Cellular Therapies and we are always looking for talented individuals who share our values to join our team. Please explore open positions by clicking the “Jobs” tab above.

Intrance Medical Systems, Inc., is a private, U.S.-based biopharmaceutical company focused on the development and commercialization of its lead clinical product for the treatment of advanced Parkinson's disease in the U.S., Canada, South America, Japan and Taiwan. Intrance's lead product, known as Lecigon® in the European market, is a fixed-dose combination treatment of levodopa, carbidopa and entacapone for enteral infusion in advanced Parkinson's disease patients. The company is rapidly advancing its streamlined U.S. clinical development program in this target indication. Our team is comprised of industry veterans with extensive expertise in advanced Parkinson's disease including proven track records in regulatory, clinical development and commercialization. Intrance is backed by a strong syndicate of investors. The product, which was acquired by a neurology specialty pharma company for commercialization in Europe, has been rapidly gaining market share and user acceptance.

Intrommune Therapeutics, Inc. is a biotechnology company located in New York, NY. Intrommune is developing food allergy immunotherapies that are delivered while you brush your teeth, a lifelong habit that is ingrained in most people and ensures daily use of our product. Intrommune's elegant new treatment platform for food allergies is expected to be safe, effective and convenient. Intrommune’s first product is a therapy for patients who suffer fro​m peanut allergy. Intrommune is developing the oral mucosal immunotherapy (OMIT) platform for food allergies. It is a long-term solution for the 220 million, including 32 million people in the U.S., who suffer from this life-altering condition.

ITB-MED is developing the proprietary antagonistic CD2-directed monoclonal antibody, TCD601 (siplizumab), for several indications. The lifelong need for immunosuppression after transplantation negatively affects both patient health and the transplanted organ. Clinical Trials are being executed globally with a particular focus on improving patient health post-transplantation.

At Kallyope, we focus on big health challenges that matter to patients and families. We aim to discover and develop effective, easy to use, and well-tolerated oral agents addressing metabolic, neurological, and gastrointestinal diseases. Inside every human body is a complex, unexplored network of metabolic, neurological, and gastrointestinal interconnections. Our scientists are unlocking the mysteries of this network to develop oral therapies for obesity and diabetes; neurological disorders, including migraine; and gastrointestinal disease, including celiac disease. Based in New York City, we are home to some of the world’s most intrepid scientific minds from the world’s top institutions, working alongside a seasoned team with a proven track record of success in drug discovery and development. Together, we are leveraging multiple sophisticated technologies and internally-developed capabilities to bring fundamentally new solutions to some of the most pressing unmet needs in human health.

Kinevant Sciences is on a mission to transform the lives of people living with rare inflammatory diseases through high-impact medicine. Kine is a word from Ancient Greece meaning “to move” or “set in motion,” which defines our purpose of moving safe and accessible therapeutics forward, so patients feel empowered to take back full control of their lives. Our approach combines patient-forward thinking, scientific rigor and clinical excellence to overcome some of the most deep-rooted barriers to treatment within underserved populations by delivering disease-modifying therapeutics that are safe, well tolerated and easily accessible. Our lead product candidate, namilumab, is an investigational monoclonal antibody being developed for treatment of sarcoidosis. Namilumab has the potential to address the underlying disease pathology by targeting GM-CSF, a key pro-inflammatory cytokine and growth factor implicated in the pathogenesis of sarcoidosis and other inflammatory disorders. Kinevant has initiated two actively enrolling clinical trials to investigate namilumab as a potential new treatment for sarcoidosis to significantly improve patients’ overall quality of life.

Proprietary applications in diagnostics and therapeutics. International technology development. Translational medicine impacting Immunology, Oncology and Genomics.

LB Pharmaceuticals is a development stage life sciences company devoted to commercializing novel and improved versions of successful CNS treatments used extensively overseas but never developed, approved, or marketed in the United States. We believe that there are a number of ‘gold standard’ CNS therapies with excellent safety and efficacy profiles that, for various financial reasons, have never become FDA approved. Our approach is to create a research-focused organization dedicated to generating novel intellectual property around improved versions of these former best-selling drugs. We have a low-risk, high-reward drug development business plan: invest in bringing to the US market patented, branded, first-to-market versions of standard-of-care CNS therapies currently in use worldwide.

Leal Therapeutics is a biopharmaceutical company that focuses on developing novel therapeutics for patients with major disorders of the central nervous system.

Lento Bio was formed in 2022 in partnership with Ichor Life Sciences, with the goal to develop effective, safe, and durable treatments for chronic age-related disease by using small molecules to directly target molecular damage.

Based in New York City, Lexeo Therapeutics is a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Building on groundbreaking research from Weill Cornell Medicine and the University of California San Diego, Lexeo partners with preeminent institutions on the cutting edge of gene therapy research. Using a stepwise development approach, Lexeo is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4 associated Alzheimer's disease programs, and is led by pioneers and experts with decades of collective experience in genetic medicines, rare disease drug development, manufacturing and commercialization. For more information, please visit www.lexeotx.com.

Spindle Biotech Inc. (an Applied DNA Sciences, Inc. (NASDAQ: APDN) company) is commercializing a proprietary RNA polymerase for large-scale mRNA vaccine production. Recent advances in mRNA technology have shown the growing importance of synthetic RNA in biological systems due to its desirable transient property. Typical mRNA vaccine companies spend up to 60% of their cost of goods on raw materials such as enzymes and DNA templates. Spindle's platform provides a unique solution in producing high-quality RNA on-demand and in high yield, significantly reducing the cost of goods for mRNA production.

Linus Biotechnology is a patient-centric, breakthrough science, precision exposome medicine company. Our program pipeline comprises precision exposome medicine biomarkers and target discovery across disease domains for which historically no molecular endpoints have been available in medical practice or for clinical trials, including CNS (autism spectrum disorder, amyotrophic lateral sclerosis), gastroenterology (inflammatory bowel disease), renal disease and oncology.

Lixte Biotechnology Holdings, Inc. (Lixte) is a clinical-stage public (LIXT) pharmaceutical company dedicated to discovering drugs for more effective treatments for cancer. Lixte has identified molecular signaling pathways altered in disease states and designed compounds that can safely target them in animal models. The current drug portfolio includes inhibitors of protein phosphatases that are critical to cell division and DNA damage repair and inhibitors of protein deacetylases that regulate pathways of gene expression and protein degradation. The phosphatase inhibitors enhance the effectiveness of cytotoxic anti-cancer drugs in general as well as radiation therapy making them potentially useful for the treatment of many, if not all, cancers in combination with existing standard chemotherapy regimens and the evolving targeted cytotoxic therapies of personalized cancer medicine. The lead compound LB-100 is in Phase I trial and has the potential to be first-in-class. The deacetylase inhibitors have anti-cancer activity and in model systems correct enzymes deficiencies underlying several inborn metabolic diseases including Gaucher and von Hippel-Lindau disease and neurofibromatosis type 2. Lixte's cancer drug development strategy has led to the discovery of novel compounds with the potential to be therapeutically useful against several other important but seemingly disparate diseases. The phosphatase inhibitors are in pre-clinical development for reducing the extent of tissue damage following stroke, heart attack, and septic shock; and, the deacetylase inhibitors for prevention and treatment of neurodegenerative diseases, traumatic brain injury, and topically for fungal dermatitis .

LSI SOLUTIONS®, located in beautiful Victor, New York, is a dynamic and growing medical device company that has more than doubled in size over the last seven years. - LSI SOLUTIONS® is dedicated to advancing minimally invasive therapeutics through research, development, manufacturing, and marketing proprietary products. - Company Mission: Our customer is ultimately a patient. Our technology challenges human illness. Our mission is to lead the world in surgical innovation and product delivery.

American Regent, Inc, a Daiichi Sankyo Group Company, develops, manufactures, and supplies high quality sterile injectables for healthcare providers, clinics and hospitals across the United States and Canada. We have locations in New York, Ohio, and Pennsylvania and sales territories nationwide. American Regent continues to position its business for sustainable growth, with significant investments in the modernization and expansion of our U.S. manufacturing sites. These enhancements are expected to strengthen our business and represents our commitment to the ongoing success of our company and its employees. Supporting patient health is our guiding principle and our promise is to provide the healthcare marketplace with a steady supply and broad portfolio of brand and generic specialty injectables.

MABLYTICS is a biotechnology company that specializes in developing immunotherapies using a novel target with applications in cancer research.

Manas AI is a full-stack, AI-driven drug discovery company. By harnessing the power of proprietary AI models and leveraging extensive computational infrastructure, the company aims to dramatically reduce drug discovery timelines. Co-founded by Dr. Siddhartha Mukherjee and Reid Hoffman, and a world-class interdisciplinary team that spans AI, computational chemistry, biology, and clinical research, Manas AI is on a mission to bring life-saving treatments to patients faster than ever before.

Biotech company delivering innovative precision biologics for patients with advanced, metastatic cancers

At Martin Pharmaceuticals we are passionate about bringing life-changing advances to patients with rare diseases or challenging medical conditions. We aspire every day to make a real difference in people's lives, turning hope into answers.

Matter Bio is a longevity holding company focused on preserving genome integrity As we age, our genome is constantly being damaged by exogenous and endogenous sources. Occasionally errors are missed and incorporated into the DNA in the form of mutations, structural variations, epigenetic drift, and other types of information loss. At Matter, we have assembled a world-class team of scientists and executives to help counter this critical information loss in the genome. To achieve this, we are focusing on a number of assets that address key stages in the genomic information loss continuum.

Unleashing the Power of Antibodies to Fight Cancer: We aim to unlock the full potential of antibodies and their applications, enabling breakthrough precision medicines for a wide range of diseases.

MeiraGTx is a clinical-stage gene therapy company focused on developing potentially curative treatments for patients living with serious diseases.

Our vision, to disrupt cancer with the development of highly innovative immunotherapies aimed at increasing patient survival rates MimiVax is a privately held, clinical-stage biotechnology company focused on the development and commercialization of immunotherapeutic vaccines and targeted therapies for the treatment of cancer. SurVaxM, our lead immunotherapeutic vaccine, has completed a Phase 2a clinical trial in adults with newly diagnosed glioblastoma.

MindMed is a clinical-stage biopharmaceutical company developing novel products to treat brain health disorders, with a particular focus on psychiatry, addiction, pain and neurology. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems.

Mirae Asset Global Investments operates across 15 markets, where we take a collaborative approach in managing a fully diversified investment platform that spans all major asset classes. Powered by a unique perspective and the expertise of our global investment professionals, we adapt to our clients’ evolving needs, providing them with innovative investment solutions and intelligent ways to achieve their investment objectives. We currently invest over $256bn on behalf of clients, giving us the scale and experience to identify opportunities in a changing world. (Data as of June 2024) Important information: http://www.miraeasset.com/other/social-media-policy

NanoVibronix Inc. is a medical device company that is focused on creating medical products utilizing its proprietary low intensity acoustic technology. The company's patented technology allows for creation of miniature transducers that transmit low-frequency, low-intensity ultrasound through flexible material surfaces. This unique development may be utilized for a variety of medical requiring low cost therapeutic ultrasound applications. The company's patch based product diagnosis, PainShield®, carries an FDA clearance. NanoVibronix catheter based products include the CathbotTM . NanoVibronix Inc. is located in Elmsford, NY. Its subsidiary, NanoVibronix Ltd. is located in Nesher, Israel.

NeoMatrix Therapeutics, Inc. is a clinical-stage company dedicated to discovering and developing novel therapeutic agents for the treatment of serious burn injuries. They focus on developing bioactive peptides that prevent injury progression and rescue tissue from further damage.

Nephrogen is a therapeutics company developing transformative medicines for kidney disease. Their initial focus is on gene therapy for autosomal dominant polycystic kidney disease (ADPKD).

Neurogene is focused on developing life-changing genetic medicines for patients & families affected by rare, devastating neurological diseases.

New Amsterdam Sciences is a development-stage bioscience company focused on the research, development and licensing of analogues of Substance P. NAS911B is the company's lead compound, and is being pursued for indications including idiopathic pulmonary fibrosis, influenza infection, wound healing and solid tumors. New Amsterdam Sciences is devoted to developing products for both the commercial market and government markets, with exceptional candidates for mass-casualty biodefense applications specifically addressing acute radiation sickness (neutropenia), chemical exposure and biological warfare scenarios. To complete this mission, the company has cultivated numerous study partnerships with industry and academic leaders, including the Vaccine and Gene Therapy Institute of Florida, the University of Rochester, Harvard School of Medicine, and more. For additional information, please visit www.newamsterdamsciences.com

NILO Therapeutics is an early-stage biotech company developing groundbreaking therapies for autoimmune and inflammatory diseases. Our experienced team brings together diverse interdisciplinary expertise to modulate immune responses via activation of neural circuits. United by our passion for discovering and translating novel biology, we are dedicated to advancing human health through transformative science.

NomoCan Pharmaceuticals offers first-in-kind targeted therapies for some of the most aggressive cancers with unmet medical need. Our platform technology not only makes available a selective and specific diagnostic and prognostic test for early detection, but more remarkably, it introduces a highly effective therapeutics for the treatment of various cancers in order to “Bring Hope” to patients affected by this devastating disease.​

NuBiyota is a microbiome therapeutics company focused on the development of novel microbiota-based drugs to restore crucial gut equilibrium. An imbalance in this crucial ecosystem is associated with infections, chronic disease and even neurological dysfunction. NuBiyota is developing a new class of microbiome therapeutics, with multi-strain microbiota candidates for effective microbiota diversity restoration to suppress flares or promote remission in numerous indications

Olatec is a privately held biopharmaceutical company developing a platform of safe, oral NLRP3 antagonist therapeutics, to treat and prevent a broad spectrum of acute and chronic inflammatory diseases that are known to be mediated by Interleukin-1 (IL-1), including: arthritis, heart failure, asthma, Alzheimer’s disease, multiple sclerosis, type-2 diabetes, melanoma and breast cancers, among others. By selectively targeting NLRP3, the body’s first line response in the innate immune system, Olatec’s lead compound, dapansutrile (lab code: OLT1177®) inhibits the production of pro-inflammatory cytokines IL 1B and IL 18. Olatec’s drug development team, working together over 10 years, is comprised of experienced management and international thought leaders that have unparalleled expertise in inflammation and immunology and have been involved in the discovery and development of first-line inflammation treatments in the market today. The Company conducts operations in the United States and Europe and maintains offices in New York and the Netherlands.

Olatec is a privately held biopharmaceutical company developing a platform of safe, oral NLRP3 antagonist therapeutics, to treat and prevent a broad spectrum of acute and chronic inflammatory diseases that are known to be mediated by Interleukin-1 (IL-1), including: arthritis, heart failure, asthma, Alzheimer’s disease, multiple sclerosis, type-2 diabetes, melanoma and breast cancers, among others. By selectively targeting NLRP3, the body’s first line response in the innate immune system, Olatec’s lead compound, dapansutrile (lab code: OLT1177®) inhibits the production of pro-inflammatory cytokines IL 1B and IL 18. Olatec’s drug development team, working together over 10 years, is comprised of experienced management and international thought leaders that have unparalleled expertise in inflammation and immunology and have been involved in the discovery and development of first-line inflammation treatments in the market today. The Company conducts operations in the United States and Europe and maintains offices in New York and the Netherlands.

Oligomerix is an emerging biotechnology company focused on developing disease-modifying therapeutics for neurodegenerative diseases characterized by aberrant tau protein ranging from rare tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer’s disease. With a focus on oral, small molecule, tau self-association inhibitors, Oligomerix seeks to develop therapies for Alzheimer’s disease and other dementias that are easy to administer and cost effective, and which are expected to significantly add to newly emerging high-cost therapeutic options such as the monoclonal antibody targeted against beta-amyloid that was recently approved by the U.S. FDA. Oligomerix is headquartered at the Westchester Park Center in White Plains, New York and has lab facilities at the Ullmann Research Center for Health Sciences within the Albert Einstein College of Medicine.

Oncolyze is developing therapeutics that exploit a novel mechanism of action for the targeted and selective lysis of cancer cells and cancer stem cells.

OnCusp Therapeutics is transforming a growing portfolio of cutting-edge molecules into innovative treatments that deliver help and hope to cancer patients worldwide. The company is led by a founding team that has deep experience in business development, clinical development and building start-up biopharmaceutical company. OnCusp continually strives to optimize the largest value inflection point in the drug development value chain and believes that accelerating oncology drug innovation is the best way to deliver help and hope to cancer patients worldwide. OnCusp completed a $25m seed round from investors including Sequoia Capital China, Biotrack Capital, Oriza Seed Fund, and AIHC Capital. OnCusp has offices in New York and Shanghai.

A small, privately-held, and family-focused neonatology pharmaceutical company, ONY Biotech is a leader in the creation of critically important products for the treatment of premature infants. We innovate with a singular purpose: to improve outcomes for premature babies and their families. As a USA-born neonatology biotech, we take pride in the work we do delivering treatments that serve families here in the United States and around the world.

Oramed Pharmaceuticals (NASDAQ:ORMP) is developing proprietary technology for the oral delivery of drugs presently administered by way of injection. Through its patented flagship product, an orally ingestible insulin capsule currently in Phase 3 trials under the USFDA, the Company is seeking to revolutionize the treatment of diabetes. Read more: http://www.oramed.com/investors/corporate-presentation Watch: https://www.youtube.com/watch?v=5qChxTDV9eg Terms and conditions and privacy policy: https://www.oramed.com/web-site-terms-and-conditions/

Oravax Medical is developing an oral COVID-19 vaccine. The Oravax technology seamlessly integrates a novel approach to vaccines with a proprietary oral delivery platform. Oravax's COVID-19 vaccine candidate benefits from being a virus like particle (VLP) triple antigen vaccine that targets three structural proteins, which should make it a better candidate for protection across emerging mutations of the coronavirus. The oral delivery of the vaccine ought to allow for widescale inoculation and easier distribution of the vaccine without requiring an injection. Oravax was established by Oramed Pharmaceuticals Inc., the largest shareholder in Oravax, along with Premas Biotech with a mission of bringing an oral COVID-19 vaccine to the market.

OverT Bio is a biotech company focused on developing cell therapies for solid tumors. The company aims to enable the curative potential of cell therapies through innovative genetic modifications and reprogramming of immune cells.

Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders. Ovid has a broad pipeline of potential first-in-class medicines. Ovid’s most advanced investigational medicine, OV101 (gaboxadol), is currently in phase 3 clinical development for the treatment of Angelman syndrome with data expected in the 4Q 2020 and in earlier clinical development for Fragile X syndrome. Ovid is also developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare developmental and epileptic encephalopathies (DEEs) and expects to initiate pivotal trials for OV935 in 2021.

Oviva is a premier biotech company developing first-in-class therapeutics to improve ovarian function and consequently extend female healthspan. Oviva is leading a movement to improve women’s experience of aging through biomedical research, clinical development and advocacy. While driving tangible progress through therapeutics programs, Oviva is engaging with scientists, clinicians, policy makers and the general public to elevate, and equalize, the conversation around women’s health. In bringing together stakeholders across disciplines, we are inviting diverse perspectives and skill sets to drive innovation and progress in this space.

Owkin is an AI biotechnology company that uses AI to find the right treatment for every patient. We combine the best of human and artificial intelligence to answer the research questions shared by biopharma and academic researchers. By closing the translational gap between complex biology and new treatments, we bring new diagnostics and drugs to patients sooner. We use AI to identify new treatments, de-risk and accelerate clinical trials and build diagnostic tools. Using federated learning, a pioneering collaborative AI framework, Owkin enables partners to unlock valuable insights from siloed datasets while protecting patient privacy and securing proprietary data. Owkin was co-founded by Thomas Clozel MD, a former assistant professor in clinical onco-hematology, and Gilles Wainrib, a pioneer in the field of machine learning in biology, in 2016. Owkin has raised over $300 million and became a unicorn through investments from leading biopharma companies (Sanofi and BMS) and venture funds (Fidelity, GV and BPI, among others).

OYAGEN is a biotechnology company formed on September 5, 2003, for the purpose of discovering, developing, and commercializing novel pharmaceutical therapies that seek to exploit RNA editing and DNA editing enzymes. OyaGen holds exclusive rights to important technologies originating from the University of Rochester Medical Center (URMC), the Thomas Jefferson University (TJU), and Oregon Health Science Center. Over the past decade, a series of research advances have identified two families of related enzymes known as Editing Enzymes. These enzymes are endogenous cellular proteins, which chemically alter RNA or DNA molecules and thereby change the genetic code. OyaGen believes that there is a significant opportunity to “harness the editing process” to create therapies for a number of disease states. OyaGen’s initial therapeutic focus is a novel approach to the treatment of Human Immunodeficiency Virus (HIV). This initial focus on HIV is driven by a series of ground breaking discoveries that: -Identified an Editing Enzyme present in immune system -Determined that HIV inhibits this Editing Enzyme as a vital part of the infection cycle -Demonstrated that allowing this Editing Enzyme to function halts HIV OyaGen will pursue several proprietary assays in high throughput screening strategies for drug development. OyaGen seeks to bring to market the anti-HIV drugs targeting Vif and APOBEC3G that solve the problems of viral resistance, a major shortcoming of all current therapies. In the long run, the Company will draw on its core expertise in Editing Enzyme technologies to develop therapies for other disease states. OyaGen offers method development and testing as a fee-for-service to academic/educational institutions and to industry. OyaGen staff will provide expert consulting services in assay development, biochemistry, structural biology, cell biology, virology for high throughput drug discovery, drug development as well as advice in preparing federal grants.

Paratus Sciences is unlocking novel disease targets and accelerating drug discovery by leveraging the extraordinary adaptive biology of bats. Bats' numerous evolutionary adaptations allow them to resist developing many diseases, and also endow them with remarkable physiological fitness and longevity. At Paratus, we are utilizing these unique biological advantages as a roadmap to potentially address a broad spectrum of significant challenges to human health. Our proprietary discovery platform, which fully integrates cell biology, genomics, and informatics, empowers us with massive data inputs through which we are able to compare the evolved patterns of disease resistance and health management in bats with patterns of disease development and progression in humans. Through this data-driven comparative analysis, we aim to rapidly identify and prioritize novel targets and develop innovative therapeutics that can mimic bats' adaptations in order to address or prevent human disease. Our initial discovery pipeline focuses on immunology and inflammation, and cardiometabolism, with the potential to expand to additional therapeutic areas, including oncology and aging. We also have an ongoing research collaboration with the National Institute of Allergy and Infectious Disease to explore virology applications with our approach. Our top-tier investor syndicate, including Polaris Partners, ARCH Venture Partners, ClavystBio, EcoR1 Capital, Leaps by Bayer, and Alexandria Venture Investments, and the $100 million we've raised to date, demonstrate a strong belief in the potential of our approach to impact and improve human health.

Perception Neuroscience is developing PCN-101 (Arketamine, or R-ketamine) with a vision of providing significantly improved solutions to serious mental health disorders.

Perseus Therapeutics, Inc. is at the forefront of innovation, dedicated to advancing the field of hair restoration. With a deep commitment to improving the lives of individuals who have experienced hair loss due to chemotherapy or for cosmetic reasons, our mission is to offer effective, science-backed solutions that empower confidence and well-being.

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women’s health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Phoenix Nest Biotech is a biotechnology company that focuses on treating Sanfilippo Syndrome by collaborating with leading academics and utilizing licensed key technologies.

POP Biotechnologies, Inc is Buffalo NY biotechnology company focused on the development of innovative biomedical solutions harnessing next generation nanotechnologies.

Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from neurological illnesses. We are building the only brain–computer interface that is designed to be minimally invasive, safely removable, and capable of processing large amounts of data.

Prevail Therapeutics was acquired by Eli Lilly and Company. At Prevail Therapeutics, we are developing a pipeline of gene therapies to slow or stop the underlying disease process for patients with Parkinson’s disease and other neurodegenerative disorders. We are leveraging recent breakthroughs in human genetics that point to potential disease-modifying targets for neurodegenerative diseases. Our programs utilize a precision medicine approach targeting patient populations with urgent unmet needs, where there are currently no available therapies that modify the progressive course of their disorders.

Progyny (Nasdaq: PGNY) is a transformative fertility, family building and women's health benefits solution, trusted by the nation's leading employers, health plans and benefit purchasers. We envision a world where everyone can realize their dreams of family and ideal health. Our outcomes prove that comprehensive, inclusive, and intentionally designed solutions simultaneously benefit employers, patients and physicians. Our benefits solution empowers patients with concierge support, coaching, education, and digital tools; provides access to a premier network of fertility and women's health specialists who use the latest science and technologies; drives optimal clinical outcomes; and reduces healthcare costs. Headquartered in New York City, Progyny has been recognized for its leadership and growth as a TIME100 Most Influential Company, CNBC Disruptor 50, Modern Healthcare's Best Places to Work in Healthcare, Forbes' Best Employers, Financial Times Fastest Growing Companies, Inc. 5000, Inc. Power Partners, and Crain's Fast 50 for NYC. For more information, visit www.progyny.com.

ProJenX is a clinical-stage biotechnology company with novel, targeted, brain-penetrant therapies to address neurodegenerative diseases, with an initial focus on ALS. ProJenX was created out of a long-term research collaboration between Project ALS and Columbia University to rapidly develop and commercialize its lead therapy candidate, prosetin, for people with ALS. At the heart of ProJenX’s discoveries is an innovative, patient-specific, cell-based discovery platform that can be leveraged for the creation of additional transformative neuroscience medicines.

Promontory Therapeutics is a private, clinical stage biopharmaceutical company founded in 2010, and funded by private investors and family investment offices in the U.S., Europe and Asia. It holds the exclusive, global license to phosphaplatins, a family of novel agents currently in clinical development for the treatment of both solid tumors and hematological cancers. Phosphaplatins are the result of over 20 years of work by the inventor, and uniquely combine an immunological form of apoptosis with an attractive safety profile. The lead agent is the subject of two approved IND applications with the US FDA, and of a collaboration and option agreement for rights in Greater China with SciClone Pharmaceuticals.

ProPhase Labs Inc. (Nasdaq: PRPH) ("ProPhase") is a next-generation biotech, genomics and diagnostics company. Our goal is to create a healthier world with bold action and the power of insight. We're revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, while developing potential game changer diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Our world-class CLIA labs and cutting-edge diagnostic technology provide wellness solutions for healthcare providers and consumers. We develop, manufacture, and commercialize health and wellness solutions to enable people to live their best lives. We are committed to executional excellence, smart diversification, and a synergistic, omni-channel approach.

Protagenic Therapeutics, Inc., a pre-clinical biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound, PT00114 is a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company was founded in 2016 and is based in New York, New York.

Protara Therapeutics, Inc., a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is based in New York, New York.

Pulmokine engaged in developing novel kinase inhibitors and other molecules for the treatment of pulmonary arterial hypertension.

Q BioMed Inc. is a biotech acceleration and commercial stage company. We are focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q BioMed is dedicated to providing these assets the strategic resources, developmental support, and expansion capital needed to ensure they meet their developmental potential, enabling them to provide products to patients in need‏.

Quadrant Biosciences is an epigenetic diagnostics company with a focus on the early detection of neurological disorders and other large-scale health issues. Revolutionary advancements in the early detection of autism spectrum disorder, Parkinson's disease, and mTBI, through the application of the Clarifi® epigenetic diagnostic platform, could have a significant impact on the way clinicians approach the diagnosis and treatment of these serious conditions. In March 2020, we made the decision to pivot and allocate some of our resources to directly address the pandemic. By leveraging our expertise in RNA analysis, we have been able to be part of three exciting COVID-19 projects to aid in the detection of COVID-19 in individuals and communities across the U.S. In September 2020, The Clarifi COVID-19 Test Kit obtained Emergency Use Authorization (EUA) by the Food and Drug Administration (FDA) to be used for the diagnosis fo SARS-CoV-2.

Founded in 2017, Redesign Science is a platform biotech working at the interface of physics-based molecular simulation and deep learning to create generative AI for drug discovery. We deploy our platform technology to develop first-in-class Protein Interaction Modulators against validated targets known to drive progression of multiple oncogenic and inflammatory diseases.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Remedy Pharmaceuticals, Inc., located in New York City, is a late-stage specialty pharma focused on therapies capable of transforming treatment in the management of life-threatening brain edema-related conditions − where there are inadequate or no approved existing therapies. CNS-related edema (swelling) is a large unmet medical need that carries significant mortality, morbidity and societal burdens. Solve the problem of edema and you have taken the biggest step forward in the history of treating these patients. How large is this opportunity? For instance, there are 110,000 LHIs in the U.S. each year. CNS-related edema is present in multiple critical care indications, i.e., LHI, subarachnoid hemorrhage, intracerebral hemorrhage, traumatic brain injury, cardiac arrest, spinal cord injury, etc., as well as in chronic conditions such as brain tumors (primary and metastases). For more information, go to:http://www.remedypharmaceuticals.com

Remepy is Pioneering Hybrid Drugs™. Many medical conditions are better treated by combining pharmaceutical and non-pharmaceutical treatments. Hybrid drugs are a new type of drug asset, that combines traditional drugs with proprietary treatment protocols delivered measured and adapted using our AI capabilities. Remepy’s Digital Molecules™ are designed to be the software apps within Hybrid Drugs™. They are based on digital interventions and treatment protocols that are tailored to each medical condition and its corresponding drug and are constantly measured and tracked and personalized using advanced AI capabilities. The Digital Molecules™ enhance brain functions that balance the patient's neuro-endocrine and neuro-immunological systems and boost brain neuroplasticity, in order to optimize drug performance. We also address physical, motor, psychological, and behavioral symptoms Remepy partners with pharma companies to bring Hybrid Drugs™ to market that will combine Remepy’s Digital Molecule™ and traditional drug components.

RenBio was founded on the principle that the remarkable medical benefits of antibody therapeutics should be available to everyone, and was named one of DARPA’s “Biotech Startups of the Future” one year after opening its operations. The company was co-founded by David D. Ho, MD (Time magazine's "Man of the Year" in 1996 and recipient of the Presidential Citizens Medal) and Yaoxing Huang, PhD, visionary scientists affiliated with the Aaron Diamond AIDS Research Center and Professors at Columbia University Medical Center. RenBio is backed by the Bill & Melinda Gates Foundation, DARPA, and a syndicate of private investors, and is headquartered at the Alexandria Center® for Life Science in New York City.

Repair Biotechnologies is a preclinical biotechnology company focused on developing drugs for cholesterol and aging-related diseases. Our first-in-class Cholesterol Degrading Platform (CDP) technology is aimed at reversing atherosclerosis, familial hypercholesterolemias, and other conditions in which excess or modified cholesterol drives pathology.

Retia Medical develops and sells advanced algorithms and monitors for guiding care for high-risk surgical and critically ill patients. The Argos Cardiac Output Monitor provides consistent accuracy using Multi-Beat Analysis(TM), rapid setup, and an intuitive user interface while avoiding costly proprietary disposables. Approximately 20 million surgical intensive care patients worldwide could benefit from this technology. Based in White Plains, NY, Retia's technology was developed at Michigan State University and Massachusetts Institute of Technology and validated through extensive tests in animals and humans. With the support of a strong advisory board comprised of industry and clinical experts, Retia received FDA 510(k) clearance and launched this product in December 2018, which will help revolutionize the care of the most at-risk patients.

ReVivo Medical, LLC is an early-stage medical device development company. Our initial focus is on an array of implantable devices capable of improving treatments for back and neck pain. Our unique designs rely on the biomechanics of load sharing to promote bone fusion. They have been designed with the challenges of the surgical procedure in mind. Market Background. Lower back and neck pain are the leading causes of disability world-wide. In the United States alone, there are more than 465,000 spinal fusion surgeries (of all types) performed each year. Most conventional surgeries use interbody cages that fill the space between the vertebrae and plates (akin to splints) that are implanted to hold the vertebrae in place while the spine heals. Worldwide, the spinal fusion device market is $6.4 billion. With the current economics of medicine in the United States, additional challenges have been placed on spine surgeons. Reimbursement rates are reduced and are often tied to outcomes. Surgeons need to constantly improve their results and be more efficient in the operating room, thus they are seeking new products which add value while reducing cost. Customer Value Proposition. Our initial two flagship products, an interbody cervical cage and an anterior cervical plate are innovative, next generation designs. It is anticipated that they will:  Accelerate patient recovery time.  Reduce the complexity and time required for surgery.  Achieve manufacturing costs comparable to premium implants.  Have greater appeal than the commonly used PEEK material (for our cages).

Rocket Pharmaceuticals (NASDAQ: RCKT), Ltd is a biotechnology company focused on seeking cures through molecular and gene therapy. We are developing first-in-class treatments for patients with rare and often devastating orphan diseases using a lentiviral-based and adeno-associated virus (AAV) therapy approach. We have developed rewarding partnerships with a number of leading international research institutions as well as with centers of manufacturing and cell processing expertise, while building an internal team to drive the research, development, clinical and regulatory programs. Ultimately we aim to launch and globally commercialize innovative gene therapies in disease areas with high unmet need.

Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by building Vants – nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology. The therapies in development across our family of companies target a wide range of diseases including uterine fibroids, endometriosis, prostate cancer, Parkinson’s disease, diabetes, pulmonary arterial hypertension, and multiple rare and fatal pediatric conditions. We focus on disease areas where the magnitude of R&D investment from industry is disproportionately low relative to societal medical needs. In addition to our biopharmaceutical subsidiaries, we also build technology-focused Vants focused on improving the process of developing and commercializing medicines.

Rumi Scientific is a research-driven company focused on the discovery of drugs and innovative treatments for human genetic diseases. The company's mission is to fast-track the early stage of drug discovery using predictive models of the human brain for therapeutic success.

Founded in 2008, S1 Biopharma is developing first-in-class drugs for the treatment of sexual dysfunction and hypoactive sexual desire disorder (HSDD) in both women and men. The company’s non-hormonal therapies work uniquely by restoring the natural balance of neurotransmitters in the brain. Since our company’s inception, we have been committed to innovation, integrity, the use of the highest quality science and a deep understanding of the biology underlying these disorders to develop effective treatments with safety as a priority. See our social media community guidelines at http://bit.ly/1kLpD6M

At Sapience, we think boldly about the possibilities for treating cancer. We aim to discover and develop peptide therapeutics to address oncogenic and immunogenic dysregulation that drive cancer. Our pipeline of SPEARs™ (Stabilized Peptides Engineered Against Regulation) disrupt intracellular protein-protein interactions, enabling targeting of transcription factors which have traditionally been considered undruggable. We are advancing our lead programs, ST316, a first-in-class antagonist of β-catenin, and lucicebtide (formerly known as ST101), a first-in-class antagonist of C/EBPβ, through Phase 2 clinical trials. Please engage with us on this platform to learn more!

Schrödinger, Inc. provides computational platform to accelerate drug discovery and materials design for biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. The company operates through two segments, Software and Drug Discovery. Its segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment develops a pipeline of preclinical and clinical drug discovery programs through its computational platform in collaboration with pharmaceutical companies. Schrödinger, Inc. has strategic collaborations with Twist Bioscience Corporation; Thermo Fisher Scientific to extend the use of cryo-EM in connection within silico compound screening to accelerate drug discovery; and Bristol Myers Squibb Company to discover, develop, and commercialize therapeutics in multiple disease areas. The company was founded in 1990 and is based in New York.

Scopus BioPharma is a biopharmaceutical company developing transformational therapeutics targeting serious diseases with significant unmet medical needs.

Seed Therapeutics is pioneering the science of improving human health by creating “molecular glues”: novel therapeutics that degrade disease-causing proteins that have heretofore remained “undruggable.” Through ongoing collaborations with world-leading academic experts in the field, and in partnership with seasoned drug development and commercialization experts, Seed Therapeutics is establishing a growing pipeline of exciting drug candidates on a path to clinical and commercial success. Our mission is to positively impact human health by creating novel protein degradation therapeutics for the treatment of severe diseases for which health care professionals currently have limited options to offer to patients.

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company’s lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD). Its preclinical programs include SLS-007, an anti-alpha-synuclein peptidic inhibitor to treat patients with PD; SLS-008, an orally available antagonist for chemoattractant receptor-homologous molecule for the treatment of chronic inflammation in asthma and pediatric orphan indications; SLS-004 for the treatment of PD; SLS-010, an oral histamine H3A receptor antagonist for narcolepsy and related disorders; and SLS-012, an injectable therapy for post-operative pain management. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.

SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It also develops nelipepimut-S, a cancer immunotherapy that is in Phase 2b clinical trials for the treatment of early stage breast cancer. The company has strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. SELLAS Life Sciences Group, Inc. was founded in 2012 and is headquartered in New York, New York.

Sen-Jam Pharmaceutical is focused on improving clinical outcomes for patients battling inflammation-based diseases such as viral respiratory infections from coronaviruses such as COVID-19 and other painful inflammation and toxin-induced conditions, including arthritis, vaccinations, opioid withdrawal and even the infamous hangover. Using our patented proprietary technology of “next generation anti-inflammatories” and the accelerated 505(b)2 pathway, we’re addressing the root causes of autoimmune inflammation—much like how Ozempic targets metabolic inflammation.. Our mission: to transform how we treat inflammation and reshape the business of pain relief for the betterment of humanity..

SIGA is a leader in global health, developing medicines to prevent and treat emerging infectious diseases with high unmet medical needs. Infectious diseases pose an imminent and severe threat to global health that cannot be adequately addressed with vaccines alone. Smallpox, mpox, and other orthopoxviruses are particularly worrisome because they are highly infectious and deadly. We are developing best-in-class products to treat these infections in patients worldwide.

Sparian Biosciences is an early-stage CNS-focused biopharmaceutical company committed to developing novel, transformational therapies. Diseases of the central nervous system represent a major unmet need but recently there has been little innovation and development. Sparian was co-founded by Gavril Pasternak, MD PhD and Jeff Reich, MD to develop therapeutics targeting the brain through innovative science and novel drug discovery. Currently, we have 4 programs addressing various aspects of the opioid crisis - a crisis in urgent need of innovation. Two of our compounds come from the Pasternak Lab at Memorial Sloan Kettering Cancer Center, one comes from the USC Michelson Center for Convergent Bioscience and one comes from a collaboration with Washington University. Core to our strategy, we have ongoing scientific and clinical collaborations with MSKCC, Washington University, St. Louis College of Pharmacy, Rutgers University Medical School, University of Florida, and the U.S. Department of Defense. Sparian is based out of BioLabs@NYULangone in NYC, a national biotech incubator, and is a member of the StartupNY program.

Patients around the world are struggling with debilitating back pain, trying to avoid invasive surgeries and the potential of opioid addiction. Spine Biopharma has developed a non-surgical solution that will remove pain and restore functionality, without having to use opioids.

Spur Therapeutics (formerly Freeline Therapeutics) is a clinical-stage biotechnology company focused on developing life-changing therapies for debilitating chronic conditions. By optimizing every component of our product candidates, we are improving genetic expression and targeted delivery to realize outsized clinical results. Building on the successes of our two potential first-in-class therapies for Gaucher disease and adrenomyeloneuropathy (AMN), we’re moving from rare diseases toward more widespread conditions, including forms of Parkinson’s and dementia, and even certain cardiovascular diseases. Expanding our impact, and pushing forward to new frontiers of genetic medicine. Toward life-changing therapies, and brighter futures. Toward More™

Stablix is pioneering an entirely new field of targeted deubiquitination therapeutics (TDT) to bring transformative medicines to patients with unmet medical need. Co-located in New York City and Boston, we are a creative and multidisciplinary team of scientists, innovators and leaders dedicated to changing the way we approach drug development by establishing a powerful small-molecule modality for a wide variety of devastating diseases.

Stelexis is a Deerfield founded and solely funded New York-based cancer therapeutics company with a mission of transforming cancer therapeutics paradigm and patient care, through the discovery and development of novel drugs. Stelexis proprietary platform is focused on identifying, isolating and studying the earliest definable stem and progenitor cells, which harbor clonal properties and pre-cancerous alterations, that drive the formation of primary and recurrent human tumors. Stelexis utilizes this powerful platform as a target identification engine and drug discovery and development tool to address unmet needs in multiple cancer indications. Deerfield founded Stelexis Therapeutics in 2017 together with scientific founders, Drs. Ulrich Steidl, Evripidis Gavathiotis, Amit Verma and Roman Perez-Soler of Albert Einstein College of Medicine, Montefiore Medicine, New York and Dr. Derrick Rossi of Boston Children’s Hospital, Harvard Medical School.

Stemline Therapeutics, a wholly-owned subsidiary of the Menarini Group, is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. Stemline commercializes Elzonris®, a novel targeted treatment directed to CD123 for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare hematologic cancer, in the United States and Europe, the only approved treatment for BPDCN in the US and EU to date. Stemline also commercializes Nexpovio® in Europe, an XPO1 inhibitor for multiple myeloma originating from a licensing deal with Karyopharm. Stemline has an extensive clinical pipeline of small molecules and biologics in various stages of development for a host of solid and hematologic cancers.

This page is no longer active or monitored. We are now Sumitomo Pharma America (SMPA), a science-based, technology-driven biopharmaceutical company focused on delivering therapeutic and scientific breakthroughs in areas of critical patient need. See pinned post for our new page and follow us! ⠀⠀⠀ ⠀⠀⠀⠀ ⠀⠀⠀⠀ ⠀⠀⠀⠀ ⠀⠀⠀⠀ ⠀⠀⠀⠀ ⠀⠀⠀⠀ ⠀ ==== Sumitovant is a technology-driven biopharmaceutical company accelerating development and commercialization of novel therapies for patients with rare conditions and other diseases. Through our proprietary computing and data platforms, scientific expertise and diverse company portfolio, Sumitovant has supported development of multiple FDA-approved products and a robust pipeline of early-through late-stage investigational assets addressing unmet need in pediatrics, urology, oncology, women’s health, specialty respiratory and infectious diseases. Sumitovant is a wholly owned subsidiary of Sumitomo Pharma. Please visit our website sumitovant.com for more information on Sumitovant and our portfolio.

Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases. Synaptogenix has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease

At Synaptrix, we are pioneering accessible technologies to empower individuals with paralysis to live more independently. Our first device, Neuralis™, is a non-invasive, EEG based neural interface that allows paralyzed individuals to control the wheelchair they already use with their brain activity and eye movements. By interpreting signals from visual cortex, Neuralis™ enables intuitive and effortless wheelchair navigation. Neuralis™ is specially designed to meet the needs of paralyzed patients with conditions like ALS, spinal cord injury, MS, strokes, and other neurodegenerative conditions. It provides an affordable alternative to complex, expensive solutions that are often impractical for daily independence. At Synaptrix, we are committed to improving the quality of life for individuals with physical limitations. Through our research, we seek to contribute to the advancement of assistive technologies for patients with neurological conditions, emphasizing the importance of regaining autonomy and control over their lives.

Dynamic therapeutics immuno-oncology startup in NYC. Synthis’s team is a talented group of scientists with a groundbreaking idea to improve patient care and outcomes. As long-standing tumor immunologists, the team is passionate about the science and therapeutic power behind restoring immune function in cancer patients.

Tactiva Therapeutics is an immuno-oncology company specializing in potent cancer immunotherapy using a dual T cell receptor approach.

We envision a world where no one dies of tuberculosis. However, this cannot be achieved without improved, faster-acting, and affordable tuberculosis drug regimens that are available to all who need them. These new cures can bring renewed health, hope, and prosperity to millions. Since our inception in 2000, TB Alliance has led the global search for and development of new TB regimens, catalyzing the field and convening cross-sector partnerships to forge the progress that is urgently needed for better TB treatments.

TechnoVax is a privately held near-clinical-stage biotechnology company based in Tarrytown, NY specializing in viral vaccine development. Our mission is to create and advance towards the market safe, unique and novel vaccine technologies with no current alternatives that will revolutionize the way vaccines are developed, distributed and administered. TechnoVax has developed a next-generation technology-platform based on Virus-Like Particles (VLP) that greatly enhances and facilitates the development and production of a limitless range of vaccines targeting the prevention of respiratory diseases as well as hemorrhagic fevers, immunodeficiency and cancers. The industry strongly believes that VLP based vaccines is the technology of the future! Our vaccines pipeline has been rapidly approaching the clinical phases with 3 main candidates: - A Universal flu vaccine that will eliminate the need for annual flu vaccination and will protect faster and better against future pandemic strains; - An Inhaled Powder flu vaccine that eliminates the need for cold chain storage and distribution and could be self-administered: a greatly needed solution for the developing world; - An RSV vaccine to protect against one of the leading causes of infant and elderly hospitalizations and often results in fatalities with the elderly. We have received over $5.0 million in non-dilutive funding. We are actively pursuing strategic partnerships and are seeking funding to start human testing.

Terran Biosciences is a biotech platform company devoted to the development of therapeutics and technologies for patients with neurological and psychiatric diseases. Their portfolio includes a late-stage therapy for schizophrenia, late-stage selective serotonin 2A receptor antagonists, a drug design engine that has enabled first-in-class and best-in-class psychedelic therapies, and an AI-enabled imaging software platform.

TFC Therapeutics is developing novel biologics to target and eliminate key drivers of cancer recurrence and metastasis. We’re blending early-stage research with innovative platform design to develop next-generation treatments to eliminate the most resilient cancers and put an end to their recurrence before it begins.

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has completed a Phase 3 program for ublituximab, an investigational glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells, to treat patients with relapsing forms of multiple sclerosis (RMS).

TherapyX Inc. is changing the future of pharmaceuticals using revolutionary technology. They encapsulate large biological molecules in an orally ingestible form, allowing these molecules to remain fully intact.

TheraSource is a growing biotech company located in the Greater New York area. Our mission is to develop novel anti-inflammatory therapeutics for the treatment of human diseases. TheraSource is currently focused on the development of newly-discovered molecules to treat patients with ischemic acute kidney injury (AKI) and acute radiation injury. TheraSource's R&D unit resides at The Feinstein Institute for Medical Research, which is equipped with a state-of-the-art preclinical testing facility. Our research team currently consists of 9 scientists with MD or PhD degrees in multidisciplinary areas, including protein chemistry, cell biology, immunology, pathophysiology, and clinical medicine. The company possesses 14 utility patents covering 5 molecules to treat selected inflammatory human diseases.

The Rogosin Institute has long been recognized as one of the premier centers for the diagnosis and management of kidney disease in the country and recognized for its unique approach to the prevention, detection, and management of chronic and end-stage kidney disease. A leader in home hemodialysis, peritoneal dialysis, and in-center hemodialysis services, Rogosin is dedicated to compassionate, high quality care for people with kidney and other chronic diseases through an integrative approach that combines innovative and cutting-edge research, prevention and disease management. Through our affiliation with NewYork-Presbyterian, one of the nation's premier health care systems and #1 in New York, as ranked by U.S. News & World Report, The Rogosin Institute provides inpatient and outpatient dialysis services at NewYork-Presbyterian and at hospital locations throughout New York City. Rogosin is a key component of NewYork-Presbyterian Hospital's kidney services. Rogosin cares for patients at locations throughout Manhattan, Queens, Brooklyn, and the Bronx and operates one of the largest home dialysis programs in New York City. For more information, visit www.rogosin.org. Like us on Facebook - www.facebook.com/rogosin Follow us on Twitter - www.twitter.com/rogosin Follow us on Instagram - www.instagram.com/rogosininstitute

Tourmaline is a late-stage clinical biotechnology company driven by our mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases. In doing so, we seek to develop assets medicines that have the potential to establish new standards-of-care in areas of high unmet medical need.

Traverse Biotech develops innovative internationally sourced technologies from the pre-clinical stage through clinical proof-of-concept, driving significant value for shareholders and maximizing patient benefit.

Treadwell Therapeutics is a clinical-stage biotechnology company developing novel therapeutics for highly aggressive cancers by targeting critical tumor-specific vulnerabilities including aneuploidy and immunogenicity. The Company’s robust, internally developed pipeline includes novel small molecule drugs in single agent and combination studies. Lead candidate, CFI-400945, is a PLK4 inhibitor in multiple Phase 1 and Phase 2 trials including for TNBC, prostate cancer and AML. Additional product candidates include CFI-402257, a clinical stage TTK inhibitor, as well as CFI-402411, a preclinical HPK1 inhibitor (IND filing 1H20), which is positioned to be the first clinical stage small molecule modulator of a unique node of T cell activation and has a mechanism distinct from PD1/PDL1.

United Biomedical, Inc (UBI) is a privately held multinational biopharmaceutical company dedicated to the discovery, development and commercialization of immunotherapeutics and vaccines for chronic and infectious diseases. Our product pipeline is filled with our new line of synthetic peptide-based biologicals for the treatment and prevention of Alzheimer’s Disease, AIDS, and Allergy, along with a portfolio of animal health diseases. These products are based on our proprietary designer peptides, vaccine formulation systems, and methods to manufacture therapeutic monoclonal antibodies. Our platform technologies are also being used to develop a line of biosimilar versions of widely used protein and antibody drugs whose patents are about to expire. UBI’s proprietary designer peptide technology has been used to produce a line of blood screening diagnostics and the first successfully commercialized synthetic peptide vaccine. Additional revenue streams are generated from pharmaceutical contract manufacturing by our subsidiary UBI-Asia and various sponsorships in product development.

The University of Rochester is a private research university located in Rochester, New York. Our campuses are home to more than 6,500 undergraduates and nearly 5,500 graduate students who come from across the United States and around the world to pursue their academic goals. We offer bachelor's, master's, and doctoral degrees through our seven schools and various interdisciplinary programs. Our Yellowjackets compete in NCAA Division III for athletics. With its affiliated UR Medicine health system, we are the largest employer in the Greater Rochester area.

We are UTR Therapeutics Inc. a pre-clinical NYC based biotech born from the Nucleate Activator Program. Our technology is a breakthrough discovery which can overwrite any endogenous transcript. The technology can uniquely target and degrade any transcript of interest which we have proven in multiple difficult to treat cancers. Learn more by visiting us at www.utrtherapeutics.com or contacting us at chidi@utrtherapeutics.com Notable Recognitions 2022: Nucleate Genentech Award Illumina Accelerator Sequencing Grant 2023: Deerfield Management and Economic Development Committee of NY xSeed Award 40 under 40 in Cancer [Chidiebere Awah], Association of Value Based Cancer Care (AVBCC) July 31 2023- Pre-IND Feedback from FDA for UTRxM1-18

Vaccinex is pioneering a differentiated approach to treating neurodegenerative disease through the inhibition of semaphorin 4D (SEMA4D), a key driver of neuroinflammation. Our lead drug candidate, pepinemab, blocks SEMA4D and has potential as a disease-modifying treatment for Huntington’s, Alzheimer’s and other neurodegenerative diseases.

Verra Therapeutics is a privately held company near Ithaca NY, that was founded in 2017 with a mission of transforming the treatment of protease-driven diseases using an innovative small protein platform. Verra is developing preclinical drug candidates for Chronic Bronchitis, Acute Lung Injury and Acute Kidney Injury by adapting nature’s highly evolved design for each target protease. Dr. Christopher Prince brings decades of leadership experience to the team in managing technology companies through biotech and pharmaceutical development. Dr. Marcia Moss has a comprehensive background in drug discovery and development and is a thought leader on proteases as disease targets. Verra’s goal is to create novel, selective and impactful drugs for patients with major unsolved medical illnesses.

Visiox biopharmaceutical company focused on the development and commercialization to address highly prevalent diseases.

Vitalis is a pre-clinical stage pharmaceutical company that is dedicated to changing the treatment of multiple sclerosis, post-op pain (non-opioid), and dyslipidemia through innovative therapies. Vitalis hopes to address major side effects of some of these treatments, such as flush, while also improving outcomes.

Volastra Therapeutics is a New York-based drug discovery and therapeutics company pioneering novel approaches to treating cancer by exploiting chromosomal instability (CIN), cancer’s most targetable vulnerability. Founded by Lewis Cantley, Ph.D., Olivier Elemento, Ph.D., and Samuel Bakhoum, M.D., Ph.D., Volastra is advancing a novel synthetic lethal and immune activating pipeline. Leading its portfolio, Volastra has two KIF18A inhibitors in Phase 1 clinical trials for cancers with high levels of chromosomal instability.

Waypoint's proprietary spatial multi-omics platform enables us to solve critical issues around understanding how cell therapies navigate the three-dimensional tumor microenvironment and allow the measurement of cell-to-cell interactions.

Woolsey Pharmaceuticals is a biopharmaceutical company that provides therapeutics common diseases.

Xalud Therapeutics is a biotechnology company developing a non-viral gene therapy platform to treat pathologic inflammation through immune modulation. The company is harnessing the power of interleukin-10 (IL-10), a potent cytokine that acts as a master regulator for multiple inflammatory pathways, to address the root cause of inflammation and subsequently restore homeostasis in the immune system. Xalud’s lead product candidate, XT-150, is a locally injectable plasmid DNA gene therapy expressing IL-10 to addresses pathologic inflammation and pain.

Xylyx Bio is a regenerative medicine company focused on developing innovative approaches for tissue repair and regeneration. Through expert integration of systemic physiology, Xylyx Bio translates cutting-edge regenerative biotechnologies into first-in-class products. The company is also harnessing the power of tissue-specific extracellular matrix for applications in drug discovery and screening, in vitro disease modeling, and regenerative medicine.

Y-mAbs is late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product pipeline, including 2 pivotal-stage product candidates - naxitamab and omburtamab - which target tumors that express GD2 and B7-H3, respectively. Our mission is to become the world leader in developing antibody-based cancer products that address clear unmet needs in pediatric oncology. With the right partnerships and collaboration, we envision expanding our capabilities to treat adults - changing the course of cancer and its outcome.

We are dedicated to the discovery and development of small molecule therapeutics targeting fundamental biological pathways of cancer. Our experienced team is comprised of industry leaders with proven track records in the discovery, clinical development, and commercialization of innovative cancer therapies. Leveraging our extensive industry experience and know-how, we developed our Integrated Discovery Engine—our working model for generating potentially differentiated product candidates that are designed to target distinct cancer pathways. This approach has allowed us to advance a diverse pipeline in a capital efficient manner, clearing four INDs with the FDA in five years. We believe our deep pipeline of oncology therapeutic candidates has the potential to significantly improve the lives of patients with various types of cancer. In May 2020, we established Zentera Therapeutics, our majority-owned Chinese joint venture, to develop and commercialize three Zentalis-discovered oncology candidates (ZN-c5, ZN-c3, and ZN-d5), in addition to potential future candidates, in China. The launch of Zentera is a key milestone in our global clinical development strategy and is the first step toward advancing our potentially best-in-class therapeutic candidates to markets worldwide.

Launched by Zentalis in 2020. Zentera Therapeutics is focused on the creation of differentiated small molecule treatments targeting fundamental biological pathways of cancer.

北京东方百泰生物科技有限公司 is a pharmaceuticals company based out of 北京, 北京, China.